p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer

Conclusions: Using paired isogenic PDX-derived metastatic TNBC cells, loss of p53 promoted tumor growth and consequently increased tumor cell shedding into the blood, thus enhancing metastasis. Loss of BTG2 expression in p53-deficient tumors contributed to this metastatic potential by enhancing tumor growth in primary and metastatic sites. Furthermore, clinical data support conclusions generated from PDX models and indicate that BTG2 expression is a candidate prognostic biomarker for TNBC.

http://breast-cancer-research.com/content/18/1/13

Source: Breast Cancer Research - January 27, 2016 Category: Cancer & Oncology Authors: Emily PowellJiansu ShaoYuan YuanHsiang-Chun ChenShirong CaiGloria EcheverriaNipun MistryKeith DeckerChristopher SchlosbergKim-Anh DoJohn EdwardsHan LiangDavid Piwnica-WormsHelen Piwnica-Worms Source Type: research